Medical News

As a number of as half of patients with superficial bladder cancer do not respond to the standard first-line chemotherapy placed into the bladder, as per current multi-center outcomes data. When this happens, typically, their only option is surgical removal of the bladder. Now, scientists at the Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian Hospital and Columbia University Medical Center are investigating an FDA-approved metastatic breast-cancer drug called Abraxane that may prove a safe and effective alternative to surgery for these patients……..

Original post by Health news from medicineworld.org

As a number of as half of patients with superficial bladder cancer do not respond to the standard first-line chemotherapy placed into the bladder, as per current multi-center outcomes data. When this happens, typically, their only option is surgical removal of the bladder. Now, scientists at the Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian Hospital and Columbia University Medical Center are investigating an FDA-approved metastatic breast-cancer drug called Abraxane that may prove a safe and effective alternative to surgery for these patients……..

Original post by Health news from medicineworld.org